𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study

✍ Scribed by Gundersen, S.; Hannisdal, E.; Lundgren, S.; Wist, E.

Book ID
123361298
Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
524 KB
Volume
30
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; HΓ¨ndrΓ© C. Falkson πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high